Literature DB >> 16148430

Chiral cardiovascular drugs: an overview.

Vasant V Ranade1, John C Somberg.   

Abstract

Stereochemistry in drug molecules is rapidly becoming an important aspect in drug research, design, and development. Recently, individual stereoisomers of drug molecules with asymmetric centers such as fexofenadine, cetirizine, verapamil, fluoxetine, levalbutarol, and amphetamine, for example, have been separated and developed as individual drugs. These stereoisomers have different therapeutic activity, and each isomer has contributed differently with respect to its formulation's pharmacologic activity, side effects, and toxicity. The present overview discusses chirality among a select group of cardiovascular drugs, their stereochemical synthesis/preparation, isolation techniques using chiral chromatography, methods for confirmation of their enantiomeric purity, pharmacodynamics, and pharmacokinetics. Chirality has been visualized as an important factor in cardiovascular research. It is also becoming evident in other areas of therapeutics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148430     DOI: 10.1097/01.mjt.0000167429.37357.0c

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

1.  Comparative pharmacodynamic and pharmacokinetic study of MIDD0301 and its (S) enantiomer.

Authors:  M S Rashid Roni; Nicolas M Zahn; Gene T Yocum; Daniel A Webb; Md Yeunus Mian; Michelle J Meyer; Anika S Tylek; James M Cook; Charles W Emala; Douglas C Stafford; Leggy A Arnold
Journal:  Drug Dev Res       Date:  2022-03-04       Impact factor: 5.004

2.  Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation.

Authors:  Il-Man Kim; Douglas G Tilley; Juhsien Chen; Natasha C Salazar; Erin J Whalen; Jonathan D Violin; Howard A Rockman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-11       Impact factor: 11.205

Review 3.  Chiral Aspects of Local Anesthetics.

Authors:  Ružena Čižmáriková; Jozef Čižmárik; Jindra Valentová; Ladislav Habala; Mário Markuliak
Journal:  Molecules       Date:  2020-06-12       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.